HFB200604: BTLA Agonist
Phase I, Recruiting
Stimulating BTLA to induce immune suppression in autoimmune and inflammatory diseases
BTLA (B and T lymphocyte attenuator) is a co-inhibitory immune checkpoint structurally related to PD-1 and CTLA-4. BTLA’s expression is restricted to immune cells, including B cells, CD4+ and CD8+ T cells, and dendritic cells. Upon interaction with its ligand HVEM, BTLA induces the recruitment of SHP1 and SHP2 to suppress the proliferation and activation of B and T cells. The BTLA/HVEM interaction promotes immune tolerance, while reduced BTLA signaling has been implicated in a range of autoimmune diseases.
Our DIS® Approach
HiFiBiO’s DIS®-driven single cell immune profiling data suggests that under-stimulation of BTLA by HVEM plays a role in a host of autoimmune diseases. Therefore, BTLA agonism is an attractive approach to restore immune tolerance.
Drug Info
HFB200604 is a BTLA agonist monoclonal antibody developed to suppress activated T and B cells. In preclinical studies, HFB200604 demonstrates potent inhibition of T and B cell activation and is able to prevent graft vs. host disease (GvHD) in a humanized mouse model. HFB200604 is currently being manufactured as a subcutaneous formulation and is scheduled for IND filing in Q3 2024.